Ashwin S Nathan1,2, Lin Yang2, Nancy Yang, Sameed Ahmed M Khatana1,2,3,4, Elias J Dayoub1,2, Lauren A Eberly1,2, Sreekanth Vemulapalli5, Suzanne J Baron6, David J Cohen7, Nimesh D Desai8,2, Joseph E Bavaria8, Howard C Herrmann1, Peter W Groeneveld2,3,4, Jay Giri1,2,3,4, Alexander C Fanaroff1,2. 1. Division of Cardiology (A.S.N., S.A.M.K., E.J.D., L.A.E., H.C.H., J.G., A.C.F.), Hospital of the University of Pennsylvania, Philadelphia. 2. Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center (A.S.N., L.Y., N.Y., S.A.M.K., E.J.D., L.A.E., N.D.D., P.W.G., J.G., A.C.F.), University of Pennsylvania, Philadelphia. 3. Leonard Davis Institute of Health Economics (A.S.N., L.Y., S.A.M.K., E.J.D., L.A.E., N.D.D., P.W.G., J.G., A.C.F.), University of Pennsylvania, Philadelphia. 4. Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA (S.A.M.K., P.W.G., J.G.). 5. Duke Clinical Research Institute, Durham, NC (S.V.). 6. Lahey Hospital and Medical Center, Burlington, MA (S.J.B.). 7. St. Francis Hospital, Roslyn, New York (D.J.C.). 8. Division of Cardiac Surgery (N.D.D., J.E.B.), Hospital of the University of Pennsylvania, Philadelphia.
Abstract
BACKGROUND: Despite the benefits of novel therapeutics, inequitable diffusion of new technologies may generate disparities. We examined the growth of transcatheter aortic valve replacement (TAVR) in the United States to understand the characteristics of hospitals that developed TAVR programs and the socioeconomic status of patients these hospitals served. METHODS: We identified fee-for-service Medicare beneficiaries aged 66 years or older who underwent TAVR between January 1, 2012, and December 31, 2018, and hospitals that developed TAVR programs (defined as performing ≥10 TAVRs over the study period). We used linear regression models to compare socioeconomic characteristics of patients treated at hospitals that did and did not establish TAVR programs and described the association between core-based statistical area level markers of socioeconomic status and TAVR rates. RESULTS: Between 2012 and 2018, 583 hospitals developed new TAVR programs, including 572 (98.1%) in metropolitan areas, and 293 (50.3%) in metropolitan areas with preexisting TAVR programs. Compared with hospitals that did not start TAVR programs, hospitals that did start TAVR programs treated fewer patients with dual eligibility for Medicaid (difference of -2.83% [95% CI, -3.78% to -1.89%], P≤0.01), higher median household incomes (difference $2447 [95% CI, $1348-$3547], P=0.03), and from areas with lower distressed communities index scores (difference -4.02 units [95% CI, -5.43 to -2.61], P≤0.01). After adjusting for the age, clinical comorbidities, race and ethnicity and socioeconomic status, areas with TAVR programs had higher rates of TAVR and TAVR rates per 100 000 Medicare beneficiaries were higher in core-based statistical areas with fewer dual eligible patients, higher median income, and lower distressed communities index scores. CONCLUSIONS: During the initial growth phase of TAVR programs in the United States, hospitals serving wealthier patients were more likely to start programs. This pattern of growth has led to inequities in the dispersion of TAVR, with lower rates in poorer communities.
BACKGROUND: Despite the benefits of novel therapeutics, inequitable diffusion of new technologies may generate disparities. We examined the growth of transcatheter aortic valve replacement (TAVR) in the United States to understand the characteristics of hospitals that developed TAVR programs and the socioeconomic status of patients these hospitals served. METHODS: We identified fee-for-service Medicare beneficiaries aged 66 years or older who underwent TAVR between January 1, 2012, and December 31, 2018, and hospitals that developed TAVR programs (defined as performing ≥10 TAVRs over the study period). We used linear regression models to compare socioeconomic characteristics of patients treated at hospitals that did and did not establish TAVR programs and described the association between core-based statistical area level markers of socioeconomic status and TAVR rates. RESULTS: Between 2012 and 2018, 583 hospitals developed new TAVR programs, including 572 (98.1%) in metropolitan areas, and 293 (50.3%) in metropolitan areas with preexisting TAVR programs. Compared with hospitals that did not start TAVR programs, hospitals that did start TAVR programs treated fewer patients with dual eligibility for Medicaid (difference of -2.83% [95% CI, -3.78% to -1.89%], P≤0.01), higher median household incomes (difference $2447 [95% CI, $1348-$3547], P=0.03), and from areas with lower distressed communities index scores (difference -4.02 units [95% CI, -5.43 to -2.61], P≤0.01). After adjusting for the age, clinical comorbidities, race and ethnicity and socioeconomic status, areas with TAVR programs had higher rates of TAVR and TAVR rates per 100 000 Medicare beneficiaries were higher in core-based statistical areas with fewer dual eligible patients, higher median income, and lower distressed communities index scores. CONCLUSIONS: During the initial growth phase of TAVR programs in the United States, hospitals serving wealthier patients were more likely to start programs. This pattern of growth has led to inequities in the dispersion of TAVR, with lower rates in poorer communities.
Authors: Mohamad Alkhouli; David R Holmes; John D Carroll; Zhuokai Li; Taku Inohara; Andrzej S Kosinski; Molly Szerlip; Vinod H Thourani; Michael J Mack; Sreekanth Vemulapalli Journal: JACC Cardiovasc Interv Date: 2019-05-27 Impact factor: 11.195
Authors: Karen E Joynt Maddox; Mat Reidhead; Jianhui Hu; Amy J H Kind; Alan M Zaslavsky; Elna M Nagasako; David R Nerenz Journal: Health Serv Res Date: 2019-04 Impact factor: 3.402
Authors: Suzanne J Baron; Suzanne V Arnold; Kaijun Wang; Elizabeth A Magnuson; Khaja Chinnakondepali; Raj Makkar; Howard C Herrmann; Susheel Kodali; Vinod H Thourani; Samir Kapadia; Lars Svensson; David L Brown; Michael J Mack; Craig R Smith; Martin B Leon; David J Cohen Journal: JAMA Cardiol Date: 2017-08-01 Impact factor: 14.676
Authors: Harun Kundi; Kamil F Faridi; Yun Wang; Rishi K Wadhera; Linda R Valsdottir; Jeffrey J Popma; Daniel B Kramer; Robert W Yeh Journal: Circulation Date: 2019-09-09 Impact factor: 29.690
Authors: J Matthew Brennan; Martin B Leon; Paige Sheridan; Isabel J Boero; Qinyu Chen; Angela Lowenstern; Vinod Thourani; Sreekanth Vemulapalli; Kevin Thomas; Tracy Y Wang; Eric D Peterson Journal: J Am Heart Assoc Date: 2020-08-11 Impact factor: 5.501
Authors: Ashwin S Nathan; Lin Yang; Nancy Yang; Lauren A Eberly; Sameed Ahmed M Khatana; Elias J Dayoub; Sreekanth Vemulapalli; Howard Julien; David J Cohen; Brahmajee K Nallamothu; Suzanne J Baron; Nimesh D Desai; Wilson Y Szeto; Howard C Herrmann; Peter W Groeneveld; Jay Giri; Alexander C Fanaroff Journal: JAMA Cardiol Date: 2022-02-01 Impact factor: 14.676